Weekly Analysts’ Ratings Changes for ALX Oncology (ALXO)

Several brokerages have updated their recommendations and price targets on shares of ALX Oncology (NASDAQ: ALXO) in the last few weeks:

• 3/7/2025 – ALX Oncology had its price target lowered by analysts at Stifel Nicolaus from $3.00 to $1.50. They now have a “hold” rating on the stock.
• 3/7/2025 – ALX Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
• 3/6/2025 – ALX Oncology had its price target raised by analysts at Piper Sandler from $8.00 to $9.00. They now have an “overweight” rating on the stock.
• 3/6/2025 – ALX Oncology was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $3.00 price target on the stock, up previously from $2.00.
• 1/27/2025 – ALX Oncology had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a “buy” rating on the stock.
• 1/24/2025 – ALX Oncology had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 1/24/2025 – ALX Oncology had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a “buy” rating on the stock.

ALX Oncology Price Performance

ALX Oncology stock traded down $0.04 on Monday, reaching $0.79. The company’s stock had a trading volume of 228,081 shares, compared to its average volume of 979,087. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The company has a market cap of $42.07 million, a price-to-earnings ratio of -0.26 and a beta of 1.01. The business’s fifty day moving average price is $1.31 and its 200 day moving average price is $1.55. ALX Oncology Holdings Inc. has a twelve month low of $0.78 and a twelve month high of $17.83.

Hedge Funds Weigh In On ALX Oncology

Several large investors have recently made changes to their positions in ALXO. Almitas Capital LLC acquired a new position in ALX Oncology in the fourth quarter valued at about $2,042,000. Bank of America Corp DE increased its holdings in shares of ALX Oncology by 492.9% in the fourth quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock worth $1,729,000 after acquiring an additional 860,703 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of ALX Oncology in the fourth quarter worth about $1,380,000. Two Sigma Advisers LP increased its holdings in shares of ALX Oncology by 64.6% in the fourth quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock worth $1,376,000 after acquiring an additional 323,400 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of ALX Oncology by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 740,106 shares of the company’s stock worth $1,236,000 after acquiring an additional 39,259 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.